Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
By MD Adriaan J. van der Meer, MD Bart J. Veldt, PhD Jordan J. Feld, P. Md, P. Dufour, P. Lammert, PhD Andres Duarte-Rojo, MD E. Jenny Heathcote, Peter Manns, PhD Lorenz Kuske and 5 more. Journal of the American Medical Association (JAMA), 2012
1,691 citations recorded by the source corpus.
Subfields: Epidemiology, Hepatology
View Paper: https://www.semanticscholar.org/paper/064fe383503bfeb68dee72d1320ba5f025eedba9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
- A. Jemal
- Aasld Idsa Hcv Guidance Panel
- Christoph Sarrazin
- J. Llovet
- Peter R. Galle
- A. Aghemo
- G. Dusheiko
- V. Mazzaferro
In Hepatology
- J. Llovet
- V. Mazzaferro
- Alejandro Forner1 , 2
- Peter R. Galle
- F. Piscaglia
- J. Raoul
- Aasld Idsa Hcv Guidance Panel
- Christoph Sarrazin
Citations in the corpus
- EASL Recommendations on Treatment of Hepatitis C 2015. (2015, background): “Recent data suggest that the risk of HCC and all-cause mortality is significantly reduced, but not eliminated, in cirrhotic patients who clear HCV compared to untreated patients and nonsustained virological responders [2,3].”
- Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus (2015, background): “These reductions in disease severity contribute to dramatic reductions in all-cause mortality.(43,52) Lastly, patients achieving an SVR have substantially improved quality of life, including physical, emotional, and social health.”
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, background): “In hepatitis C viral infection, all-cause mortality and the risk of HCC is reduced among patients with HCV who achieve a sustained virological response (SVR) with interferon-based antiviral therapy.(62) Meta-analyses of interferon-based therapies showed a more than 70% reduction in HCC incidence (ab”
- Annual Report to the Nation on the Status of Cancer, 1975–2012, Featuring the Increasing Incidence of Liver Cancer (2016, positive): “106,107 In addition to appropriate medical care and management for HCV infection, other strategies to reduce the burden of liver cancer in the United States include promoting hepatitis B vaccination strategies; reducing unhealthy behaviors, such as tobacco use and excessive alcohol use; and…”
- EASL recommendations on treatment of hepatitis C - Final update of the series. (2020, background): “Recommendations for HCV testing in this population are based on the high prevalence of infection,(272,273) the demonstration that awareness of their HCV status induces sustained protective behavioural changes,(274,275) the potential public health benefit of reducing transmission by treating current ”
- EASL Recommendations on Treatment of Hepatitis C 2016. (2017, background): “The goal of therapy is to eradicate HCV infection to prevent hepatic cirrhosis, decompensation of cirrhosis, HCC, and death.”
- EASL Recommendations on Treatment of Hepatitis C 2018. (2018, background): “After 12 weeks of therapy, 95% (20/ 21; no virological failure) of them achieved an SVR.107 In another phase II trial, patients were treated with the combination of sofosbuvir and ledipasvir for 12 weeks.”